The pharmacological studies are consistent with previous reports of GDF15 transgenic mice being resistant to high fat diet-induced obesity (DIO) and glucose intolerance [11–14], supporting a therapeutic role of high levels of exogenous GDF15 in obesity and diabetes management. This evidence concerns the gene GDF15 and obesity disorder.